Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26505364 | 0.92 | ALDH1A1 (0.50) | GNAO1HRH3MAPTCHRM1CHRM5 | |
| Cyanide SCHEMBL30213081 | 0.81 | GNAO1 (0.61) | GNAO1HRH3CHRM1CHRM5CHRM3 | |
| SCHEMBL10282362 | 0.81 | ALDH1A1 (0.54) | GNAO1HRH3MAPTCHRM1CHRM5 | |
| SCHEMBL4387600 | 0.80 | ALDH1A1 (0.58) | GNAO1MAPTTSHRALDH1A1PKM | |
| SCHEMBL5197870 | 0.80 | GNAO1 (0.54) | GNAO1HRH3CHRM1CHRM5CHRM3 | |
| SCHEMBL4500532 | 0.80 | MAPT (0.57) | GNAO1MAPTDRD2DRD3TSHR | |
| SCHEMBL17424060 | 0.80 | GNAO1 (0.59) | GNAO1HRH3CHRM1CHRM5CHRM3 | |
| Cyanide SCHEMBL30212624 | 0.79 | GNAO1 (0.64) | GNAO1HRH3CHRM1CHRM5CHRM3 | |
| Cyanide SCHEMBL30212746 | 0.79 | GNAO1 (0.64) | GNAO1HRH3CHRM1CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL30330489 | 0.79 | GNAO1 (0.73) | GNAO1HRH3CHRM1CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102558026-A | Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1) | CGENE TECH SUZHOU CHINA CO LTD | 2012-07-11 | — | — | CN | claimed |
| CN-102558026-A | Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1) | CGENE TECH SUZHOU CHINA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| US-7485651-B2 | Compounds with activity on muscarinic receptors | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| CN-1303376-A | Compound with activity on muscarinic receptors | ACADIA PHARMACEUTICAL INC (US) | 2001-07-11 | — | — | CN | disclosed |
| WO-2001005763-A2 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | GNAO1 253/4885HRH3 54/4885MAPT 2400/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | GNAO1 253/4885HRH3 54/4885MAPT 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.